Prevalence and differentiation of hereditary breast and ovarian cancers in Japan

Seigo Nakamura, Masato Takahashi, Mitsuhiro Tozaki, Takahiro Nakayama, Tadashi Nomizu, Yoshio Miki, Yoshie Murakami, Daisuke Aoki, Takuji Iwase, Seiichiro Nishimura, Hideko Yamauchi, Shozo Ohsumi, Shinichi Baba, Tadao Shimizu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: We assembled needed data on the prevalence and characteristics of BRCA1/2 in Japan. Materials and methods: Our study of BRCA1/2 collected data at eight institutions in Japan on 320 individuals with a strong family history of breast cancer, according to the NCCN guidelines, by the end of March 2012. Results: Among 260 proband cases, 46 (17.7 %) were positive for BRCA1, and 35 (13.5 %) were BRCA2-positive. Therefore, the total pathological mutation rate was 30.7 %. Pathology data after breast surgery were obtained from 37 cases of BRCA1 mutation, 23 (62.2 %) of which were triple negative (TN). On the other hand, 29 cases (82.9 %) of BRCA2 mutations were Luminal type. The most prevalent BRCA1 mutation site was L63X, found in 10 families. L63X was reported previously by studies in Japan, and it may be a founder mutation. We found two cases of large deletion detected by multiplex ligation-dependent probe amplification. One was an entire deletion of exon 20 and the lacked exons 1–9. TN with a family history of ovarian cancer was 11/20 (55 %). TN under 40-year-old (y.o.) 15/23 (65.2 %) and TN with one or more breast cancers in family history 17/32 (53.1 %) showed higher incidences of BRCA1 mutation. Conclusion: Hereditary breast and ovarian cancer (HBOC) may have nearly the same prevalence in Japan as in the US or Europe. If TN cases are taken into account, the ratio of BRCA1 is higher. L63X may be one of the founder mutations in Japan. A nationwide database of HBOC is important to develop risk models for BRCA1/2 carriers in Japan.

Original languageEnglish
Pages (from-to)462-468
Number of pages7
JournalBreast Cancer
Volume22
Issue number5
DOIs
Publication statusPublished - 2015 Sep 7

Fingerprint

Ovarian Neoplasms
Japan
Breast Neoplasms
Mutation
Exons
Multiplex Polymerase Chain Reaction
Mutation Rate
Breast
Databases
Guidelines
Pathology
Incidence

Keywords

  • BRCA1
  • BRCA2
  • HBOC
  • L63X
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Nakamura, S., Takahashi, M., Tozaki, M., Nakayama, T., Nomizu, T., Miki, Y., ... Shimizu, T. (2015). Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer, 22(5), 462-468. https://doi.org/10.1007/s12282-013-0503-1

Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. / Nakamura, Seigo; Takahashi, Masato; Tozaki, Mitsuhiro; Nakayama, Takahiro; Nomizu, Tadashi; Miki, Yoshio; Murakami, Yoshie; Aoki, Daisuke; Iwase, Takuji; Nishimura, Seiichiro; Yamauchi, Hideko; Ohsumi, Shozo; Baba, Shinichi; Shimizu, Tadao.

In: Breast Cancer, Vol. 22, No. 5, 07.09.2015, p. 462-468.

Research output: Contribution to journalArticle

Nakamura, S, Takahashi, M, Tozaki, M, Nakayama, T, Nomizu, T, Miki, Y, Murakami, Y, Aoki, D, Iwase, T, Nishimura, S, Yamauchi, H, Ohsumi, S, Baba, S & Shimizu, T 2015, 'Prevalence and differentiation of hereditary breast and ovarian cancers in Japan', Breast Cancer, vol. 22, no. 5, pp. 462-468. https://doi.org/10.1007/s12282-013-0503-1
Nakamura S, Takahashi M, Tozaki M, Nakayama T, Nomizu T, Miki Y et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer. 2015 Sep 7;22(5):462-468. https://doi.org/10.1007/s12282-013-0503-1
Nakamura, Seigo ; Takahashi, Masato ; Tozaki, Mitsuhiro ; Nakayama, Takahiro ; Nomizu, Tadashi ; Miki, Yoshio ; Murakami, Yoshie ; Aoki, Daisuke ; Iwase, Takuji ; Nishimura, Seiichiro ; Yamauchi, Hideko ; Ohsumi, Shozo ; Baba, Shinichi ; Shimizu, Tadao. / Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. In: Breast Cancer. 2015 ; Vol. 22, No. 5. pp. 462-468.
@article{bc1f904502a94b05b08418ee2894890b,
title = "Prevalence and differentiation of hereditary breast and ovarian cancers in Japan",
abstract = "Background: We assembled needed data on the prevalence and characteristics of BRCA1/2 in Japan. Materials and methods: Our study of BRCA1/2 collected data at eight institutions in Japan on 320 individuals with a strong family history of breast cancer, according to the NCCN guidelines, by the end of March 2012. Results: Among 260 proband cases, 46 (17.7 {\%}) were positive for BRCA1, and 35 (13.5 {\%}) were BRCA2-positive. Therefore, the total pathological mutation rate was 30.7 {\%}. Pathology data after breast surgery were obtained from 37 cases of BRCA1 mutation, 23 (62.2 {\%}) of which were triple negative (TN). On the other hand, 29 cases (82.9 {\%}) of BRCA2 mutations were Luminal type. The most prevalent BRCA1 mutation site was L63X, found in 10 families. L63X was reported previously by studies in Japan, and it may be a founder mutation. We found two cases of large deletion detected by multiplex ligation-dependent probe amplification. One was an entire deletion of exon 20 and the lacked exons 1–9. TN with a family history of ovarian cancer was 11/20 (55 {\%}). TN under 40-year-old (y.o.) 15/23 (65.2 {\%}) and TN with one or more breast cancers in family history 17/32 (53.1 {\%}) showed higher incidences of BRCA1 mutation. Conclusion: Hereditary breast and ovarian cancer (HBOC) may have nearly the same prevalence in Japan as in the US or Europe. If TN cases are taken into account, the ratio of BRCA1 is higher. L63X may be one of the founder mutations in Japan. A nationwide database of HBOC is important to develop risk models for BRCA1/2 carriers in Japan.",
keywords = "BRCA1, BRCA2, HBOC, L63X, Triple negative",
author = "Seigo Nakamura and Masato Takahashi and Mitsuhiro Tozaki and Takahiro Nakayama and Tadashi Nomizu and Yoshio Miki and Yoshie Murakami and Daisuke Aoki and Takuji Iwase and Seiichiro Nishimura and Hideko Yamauchi and Shozo Ohsumi and Shinichi Baba and Tadao Shimizu",
year = "2015",
month = "9",
day = "7",
doi = "10.1007/s12282-013-0503-1",
language = "English",
volume = "22",
pages = "462--468",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Prevalence and differentiation of hereditary breast and ovarian cancers in Japan

AU - Nakamura, Seigo

AU - Takahashi, Masato

AU - Tozaki, Mitsuhiro

AU - Nakayama, Takahiro

AU - Nomizu, Tadashi

AU - Miki, Yoshio

AU - Murakami, Yoshie

AU - Aoki, Daisuke

AU - Iwase, Takuji

AU - Nishimura, Seiichiro

AU - Yamauchi, Hideko

AU - Ohsumi, Shozo

AU - Baba, Shinichi

AU - Shimizu, Tadao

PY - 2015/9/7

Y1 - 2015/9/7

N2 - Background: We assembled needed data on the prevalence and characteristics of BRCA1/2 in Japan. Materials and methods: Our study of BRCA1/2 collected data at eight institutions in Japan on 320 individuals with a strong family history of breast cancer, according to the NCCN guidelines, by the end of March 2012. Results: Among 260 proband cases, 46 (17.7 %) were positive for BRCA1, and 35 (13.5 %) were BRCA2-positive. Therefore, the total pathological mutation rate was 30.7 %. Pathology data after breast surgery were obtained from 37 cases of BRCA1 mutation, 23 (62.2 %) of which were triple negative (TN). On the other hand, 29 cases (82.9 %) of BRCA2 mutations were Luminal type. The most prevalent BRCA1 mutation site was L63X, found in 10 families. L63X was reported previously by studies in Japan, and it may be a founder mutation. We found two cases of large deletion detected by multiplex ligation-dependent probe amplification. One was an entire deletion of exon 20 and the lacked exons 1–9. TN with a family history of ovarian cancer was 11/20 (55 %). TN under 40-year-old (y.o.) 15/23 (65.2 %) and TN with one or more breast cancers in family history 17/32 (53.1 %) showed higher incidences of BRCA1 mutation. Conclusion: Hereditary breast and ovarian cancer (HBOC) may have nearly the same prevalence in Japan as in the US or Europe. If TN cases are taken into account, the ratio of BRCA1 is higher. L63X may be one of the founder mutations in Japan. A nationwide database of HBOC is important to develop risk models for BRCA1/2 carriers in Japan.

AB - Background: We assembled needed data on the prevalence and characteristics of BRCA1/2 in Japan. Materials and methods: Our study of BRCA1/2 collected data at eight institutions in Japan on 320 individuals with a strong family history of breast cancer, according to the NCCN guidelines, by the end of March 2012. Results: Among 260 proband cases, 46 (17.7 %) were positive for BRCA1, and 35 (13.5 %) were BRCA2-positive. Therefore, the total pathological mutation rate was 30.7 %. Pathology data after breast surgery were obtained from 37 cases of BRCA1 mutation, 23 (62.2 %) of which were triple negative (TN). On the other hand, 29 cases (82.9 %) of BRCA2 mutations were Luminal type. The most prevalent BRCA1 mutation site was L63X, found in 10 families. L63X was reported previously by studies in Japan, and it may be a founder mutation. We found two cases of large deletion detected by multiplex ligation-dependent probe amplification. One was an entire deletion of exon 20 and the lacked exons 1–9. TN with a family history of ovarian cancer was 11/20 (55 %). TN under 40-year-old (y.o.) 15/23 (65.2 %) and TN with one or more breast cancers in family history 17/32 (53.1 %) showed higher incidences of BRCA1 mutation. Conclusion: Hereditary breast and ovarian cancer (HBOC) may have nearly the same prevalence in Japan as in the US or Europe. If TN cases are taken into account, the ratio of BRCA1 is higher. L63X may be one of the founder mutations in Japan. A nationwide database of HBOC is important to develop risk models for BRCA1/2 carriers in Japan.

KW - BRCA1

KW - BRCA2

KW - HBOC

KW - L63X

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84940955938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940955938&partnerID=8YFLogxK

U2 - 10.1007/s12282-013-0503-1

DO - 10.1007/s12282-013-0503-1

M3 - Article

C2 - 24249303

AN - SCOPUS:84940955938

VL - 22

SP - 462

EP - 468

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 5

ER -